Related Experiment Videos
Usefulness of the TRH test in the management of patients with differentiated thyroid cancer
Tumori
|December 31, 1986
Abstract:
Thirty patients thyroidectomized for differentiated thyroid cancer were studied. Serum TSH was assayed in basal conditions and after TRH stimulation, while patients were in suppressive therapy with thyroid hormones. The basal TSH was normal in all the patients and less than 2 microU/ml in 20 patients. The TRH test was negative (no TSH response) in 27 patients and in all the cases with the basal TSH lower than 2 microU/ml.
Insights
Thyroid cancer patients on hormone therapy showed suppressed TSH levels. Most patients had no TSH response to TRH stimulation, indicating effective thyroid hormone suppression.
Area of Science:
- Endocrinology
- Oncology
- Thyroidology
Background:
- Differentiated thyroid cancer (DTC) requires long-term management.
- Thyroid-stimulating hormone (TSH) suppression is a key strategy in DTC treatment.
- Monitoring TSH levels is crucial for assessing treatment efficacy and recurrence risk.
Purpose of the Study:
- To evaluate TSH levels and response to thyrotropin-releasing hormone (TRH) stimulation in DTC patients undergoing suppressive thyroid hormone therapy.
- To determine the effectiveness of current therapeutic strategies in suppressing TSH in post-thyroidectomy DTC patients.
Main Methods:
- Study included thirty patients who underwent thyroidectomy for differentiated thyroid cancer.
- Serum TSH levels were measured under basal conditions.
- TRH stimulation tests were performed to assess TSH response in patients on suppressive thyroid hormone therapy.
Main Results:
- All patients exhibited normal basal TSH levels.
- Twenty out of thirty patients had basal TSH levels below 2 microU/ml.
- Twenty-seven patients showed a negative TRH test, indicating no TSH response.
- All patients with basal TSH below 2 microU/ml also had a negative TRH test.
Conclusions:
- TSH suppression is effectively achieved in most differentiated thyroid cancer patients on suppressive therapy.
- The TRH stimulation test is a reliable indicator of adequate TSH suppression in this patient group.
- These findings support the current therapeutic guidelines for managing differentiated thyroid cancer.